Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

.

"These data demonstrate the significant benefits that ACZ885 may provide this young population, both in steroid reduction and in extending the period these children can live free from SJIA flares," said David Epstein, Head of the Pharmaceuticals Division of Novartis. "Novartis is committed to helping improve the health of patients with SJIA and other inflammatory diseases, which is why we are delighted to be sharing these results."

ACZ885 is an investigational fully human monoclonal antibody which neutralizes the key inflammatory mediator, interleukin-1 beta (IL-1 beta), which plays an important role in a number of diseases including SJIA[5].

The incidence of SJIA is estimated to be less than 1 in 100,000 children[6]. It is called 'systemic' because the inflammation affects the whole body, as well as most of the joints[4]. The condition is characterized by potentially life-long, recurrent and painful arthritis flares, skin rashes and daily spiking fevers[2],[4].

Novartis is also presenting a number of other studies at ACR, including a second pivotal Phase III trial of ACZ885 in SJIA, which was previously presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, in September.

About the StudyThe Phase III, two-part study had an open-label, single-arm active treatment in Part I followed by a randomized, double-blind, placebo-controlled, event-driven withdrawal design in Part II[1]. A total of 177 patients between the ages of 1 and 19 years with active SJIA were enrolled in the study[1]. In Part I, patients received a subcutaneous (s.c.) dose of ACZ885 (4 mg/kg, up to 300 mg) every 4 weeks. After 8 weeks, patients who met the adapted ACR Pediatric 30 criteria began tapering (reducing) their steroid use until either: a) the dose had been decreased to less than or equal to 0.5 mg/kg[7] while maintaining the adapted ACR Pediatric 30 Criteria (successful tapering of steroids); or b)
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 “Our nation's healthcare system ... national disgrace. Furthermore, every governmental and professional entity ... deplorable state of unorganized dysfunction shares in that ... merely serve as a device to use in ... failure(s) that have accumulated through the years leading ...
(Date:8/21/2014)... DESY scientists has observed tiny quantum vortices in cold ... journal Science that the exotic vortices arrange ... is the first time that the quantum vortices, which ... is known as superfluid helium, have been detected in ... Andrey Vilesov of the University of Southern California, one ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere ... of their Nutraceutical "TELO-20 for Dogs" with ... Telomere-lengthening supplement in the world for dogs. Telomeres ... every chromosome in the body. A wealth of ... experts in Telomere Science and Aging, including Nobel ...
(Date:8/21/2014)... Aug. 21, 2014 OTC Markets ... Inc., a biotechnology company, on its approval to ... traded on OTCQX®, the best marketplace for established ... Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... successful execution of its growth strategy and achievement ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... Corporation, a spinal and orthopaedic implant and instrument company ... the launch of four new product offerings. The ... Valeo(®) C VBR, Valeo(®) Concise Cervical Plating System and ... American Spine Society (NASS) prepares to meet in San ...
... 10 Genoptix, Inc. (Nasdaq: GXDX ), a specialized ... Lazard Capital Management 6th Annual Healthcare Conference at The St. ... , Genoptix,s EVP and CFO, Doug Schuling, will ... at approximately 11:25 a.m. EST. He will provide an ...
... LOUIS, Nov. 10, 2009 The positive mix lift ... allows Monsanto Company (NYSE: MON ) to reconfirm ... 2012, Monsanto President and CEO Hugh Grant will tell ... Grant will indicate that accelerated launches for its Genuity(TM) ...
Cached Biology Technology:Amedica Announces New Product Offering 2Genoptix Announces Participation at Lazard Capital Management 6th Annual Healthcare Conference 2Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 2Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 3Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 4Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 5Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 6Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 7Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 8
(Date:8/22/2014)... and can reduce free radical damage. Can ... stress? Jianbo Zhao and co-workers from the ... China discovered that green tea polyphenol effectively ... indicating green tea polyphenols play a protective ... stress. The relevant study has been published ...
(Date:8/22/2014)... 3β-Hydroxysteroid-Δ24 reductase (DHCR24) is a multifunctional ... reticulum and has neuroprotective and cholesterol-synthesizing ... apoptosis caused by amyloid β deposition. ... Liaoning University in China constructed two ... drive DHCR24 expression specifically in neuronal ...
(Date:8/22/2014)... will finally be able to purchase fuel cell cars ... vehicles, most of the cars will run on hydrogen ... to global warming. , Now scientists at Stanford University ... ordinary AAA battery to produce hydrogen by water electrolysis. ... electrodes that split liquid water into hydrogen and oxygen ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3
... Disadvantaged urban preschoolers aren,t only at risk for failure in ... and athletic fields as well, research suggests. A new ... disadvantaged preschoolers from two urban areas showed significant developmental delays ... catching. That means that they are at risk of ...
... the sun,s rays through solar panels on their roofs used to ... order to help save the planet. But now there is no ... says a Spanish-German partnership, which has developed a virtually invisible solar ... don,t see the film at all it,s marvellous," says Francisco ...
... grapes slow what,s for many Americans a downhill sequence of ... and type 2 diabetes? Scientists at the University ... effect of grapes in reducing risk factors related to cardiovascular ... due to phytochemicals -- naturally occurring antioxidants that ...
Cached Biology News:86 percent of disadvantaged preschoolers lack basic motor skills 286 percent of disadvantaged preschoolers lack basic motor skills 3Roof integrated solar energy 2Roof integrated solar energy 3Grapes reduce risk factors for heart disease and diabetes, U-M animal study shows 2Grapes reduce risk factors for heart disease and diabetes, U-M animal study shows 3